Successful treatment of very early-developed PTLD after HLA-matched sibling HSCT with Rituximab a ca

来源 :The 35th World Congress of the International Society of Hema | 被引量 : 0次 | 上传用户:ie286
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Objective Posttransplantation Lymphoproliferative disorders (PTLD) are fatal complication after Hematopoietic Stem Cell Transplantation(HSCT).PTLD usually happen 70-90 days after HSCT.Here we report a case of very early-developed PTLD after HLA-matched sibling HSCT.
其他文献
Background Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease that can be classified by immunohistochemistry into 2 subgroups germinal center B-cell-like (GCB) or non-GCB (a subgroup inc
会议
Background Multicentric Castlemans Disease (MCD) is a very rare lymphoproliferative disorder of unknown etiology;dysregulated interleukin-6 production is a known pathogenic factor (El-Osta and Kurzroc
会议
Objective To evaluate the prognostic value of absolute lymphocyte count (ALC)and lymphocyte-to-monocyte ratio (LMR) in Diffuse large B-cell lymphoma(DLBCL) when they are diagnosised.
会议
Purpose To our knowledge,the reported studies on the reactivation of Hepatitis B virus (HBV) in NHL were mostly on DLBCL;dates on the incidence and prognostication of HBV infection and HBV reactivatio
会议
Introduction Anthracycline-containing regimens (CHOP and CHOP-like regimens) are still the cornerstone of elderly patients with diffuse large B-cell lymphoma (DLBCL),although the therapeutic response
会议
Purpose Diffuse large B cell lymphoma (DLBCL) is the most common Non-Hodgkin Lymphomas.The clinical and pathological heterogeneity of this entity makes prognostic assessment difficult.Gene expression
会议
Methods 64 patients were included in the study,from May 2013 to January 2014.Blood samples of these patients were monitoring every week.Treg,Th1 and Th17 cells number were detected by flow cytometry.S
会议
Objective To explore the main effective cells and the pathogenesis of pre-engraftment syndrome (PES) in patients with hematological malignancies after umbilical cord blood transplantation Methods We s
会议
esenchymal stromal cells (MSCs) have been developed for the prevention and treatment of graft-versus-host disease (GVHD).Non-cultured natural MSCs are considered ideal,as they better maintain their bi
会议
Background Extramedullary relapse (EMR) of Acute Leukemia (AL) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a contributor to post-transplant mortality and remains poorly
会议